Last update 21 Nov 2024
SHR-6508
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
10
Clinical Trials associated with SHR-6508A Multicenter, Randomised, Double-blind, Double-dummy Study to Assess the Efficacy and Safety of SHR6508 in Hemodialysis Subjects With Secondary Hyperparathyroidism
SHR6508注射液治疗慢性肾脏病维持性血液透析合并继发性甲状旁腺功能亢进受试者的多中心、随机、双盲双模拟、阳性药物平行对照临床试验
[Translation] A multicenter, randomized, double-blind, double-dummy, positive drug parallel controlled clinical trial of SHR6508 injection in the treatment of chronic kidney disease subjects undergoing maintenance hemodialysis combined with secondary hyperparathyroidism
SHR6508注射液治疗慢性肾脏病维持性血液透析合并继发性甲状旁腺功能亢进受试者的多中心、长期安全性及耐受性的临床研究
[Translation] A multicenter, long-term safety and tolerability clinical study of SHR6508 injection in the treatment of chronic kidney disease subjects with maintenance hemodialysis and secondary hyperparathyroidism
100 Clinical Results associated with SHR-6508
Login to view more data
100 Translational Medicine associated with SHR-6508
Login to view more data
100 Patents (Medical) associated with SHR-6508
Login to view more data
1
Literatures (Medical) associated with SHR-650801 Aug 2024Kidney International Reports
Corrigendum to “WCN24-786 PHASE I DOSE ESCALATION STUDY OF SHR6508, A CALCIUM-SENSING RECEPTOR AGONIST, IN HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM” [Kidney International Reports Volume 9, Issue 4, Supplement, April 2024, Pages S368-S369]
Author: Fan, Li ; Yang, Xinyu ; Yan, Rui ; Xing, Guangqun ; Yu, Xueqing ; Zhang, Xin ; Zhou, Linghui ; Liu, Bicheng ; Wang, Zunsong ; Wang, Deguang ; Ye, Zhiming ; Yang, Xue ; Zhao, Wei ; Zhang, Min
100 Deals associated with SHR-6508
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hyperparathyroidism, Secondary | Phase 3 | CN | 14 Jun 2024 | |
| Chronic Kidney Diseases | Phase 1 | CN | 10 Mar 2022 | |
| Nephrosis | Preclinical | CN | 20 Aug 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 54 | (wkkxfqbade) = hidjdinvrn xdptgxhgor (pmlcaengvf ) | Positive | 01 Apr 2024 | |||
Placebo | (wkkxfqbade) = mpvsquqssj xdptgxhgor (pmlcaengvf ) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free